{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:18:38Z","timestamp":1794071918984,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR190108"],"award-info":[{"award-number":["RR190108"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA190863"],"award-info":[{"award-number":["R01 CA190863"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA193362"],"award-info":[{"award-number":["R01 CA193362"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteolytic destruction is a hallmark of multiple myeloma, resulting from activation of osteoclast-mediated bone resorption and reduction of osteoblast-mediated bone formation. However, the molecular mechanisms underlying the differentiation and activity of osteoclasts and osteoblasts within a myelomatous microenvironment remain unclear. Here, we demonstrate that the osteocyte-expressed major histocompatibility complex class II transactivator (CIITA) contributes to myeloma-induced bone lesions. CIITA upregulates the secretion of osteolytic cytokines from osteocytes through acetylation at histone 3 lysine 14 in the promoter of TNFSF11 (encoding RANKL) and SOST (encoding sclerostin), leading to enhanced osteoclastogenesis and decreased osteoblastogenesis. In turn, myeloma cell\u2013secreted 2-deoxy-D-ribose, the product of thymidine catalyzed by the function of thymidine phosphorylase, upregulates CIITA expression in osteocytes through the STAT1\/IRF1 signaling pathway. Our work thus broadens the understanding of myeloma-induced osteolysis and indicates a potential strategy for disrupting tumor-osteocyte interaction to prevent or treat patients with myeloma bone disease.<\/jats:p>","DOI":"10.1038\/s41467-022-31356-7","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T11:03:14Z","timestamp":1656327794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Osteocyte CIITA aggravates osteolytic bone lesions in myeloma"],"prefix":"10.1038","volume":"13","author":[{"given":"Huan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-6381","authenticated-orcid":false,"given":"Rozita","family":"Bagheri-Yarmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc-hiep","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-hsing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Guise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Gagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-160X","authenticated-orcid":false,"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"31356_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/er.2012-1026","volume":"34","author":"SL Dallas","year":"2013","unstructured":"Dallas, S. L., Prideaux, M. & Bonewald, L. F. The osteocyte: an endocrine cell\u2026 and more. Endocr. Rev. 34, 658\u2013690 (2013).","journal-title":"Endocr. Rev."},{"key":"31356_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald, L. F. The amazing osteocyte. J. Bone Min. Res. 26, 229\u2013238 (2011).","journal-title":"J. Bone Min. Res."},{"key":"31356_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle, J., Sato, A. Y. & Bellido, T. Role and mechanism of action of sclerostin in bone. Bone 96, 29\u201337 (2017).","journal-title":"Bone"},{"key":"31356_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/nm.2452","volume":"17","author":"T Nakashima","year":"2011","unstructured":"Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231\u20131234 (2011).","journal-title":"Nat. Med."},{"key":"31356_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","volume":"76","author":"J Delgado-Calle","year":"2016","unstructured":"Delgado-Calle, J. et al. Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 76, 1089\u20131100 (2016).","journal-title":"Cancer Res."},{"key":"31356_CR6","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/0008-5472.CAN-14-2493","volume":"75","author":"JL Sottnik","year":"2015","unstructured":"Sottnik, J. L., Dai, J., Zhang, H., Campbell, B. & Keller, E. T. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res. 75, 2151\u20132158 (2015).","journal-title":"Cancer Res."},{"key":"31356_CR7","first-page":"353ra113","volume":"8","author":"H Liu","year":"2016","unstructured":"Liu, H. et al. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci. Transl. Med. 8, 353ra113 (2016).","journal-title":"Sci. Transl. Med."},{"key":"31356_CR8","doi-asserted-by":"crossref","unstructured":"H. Liu et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci. Transl. Med. 11, (2019).","DOI":"10.1126\/scitranslmed.aau9087"},{"key":"31356_CR9","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1038\/leu.2017.152","volume":"31","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle, J. et al. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia 31, 2686\u20132694 (2017).","journal-title":"Leukemia"},{"key":"31356_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni1109","volume":"5","author":"S LeibundGut-Landmann","year":"2004","unstructured":"LeibundGut-Landmann, S., Waldburger, J. M., Reis e Sousa, C., Acha-Orbea, H. & Reith, W. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nat. Immunol. 5, 899\u2013908 (2004).","journal-title":"Nat. Immunol."},{"key":"31356_CR11","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0092-8674(02)00696-7","volume":"109","author":"JP Ting","year":"2002","unstructured":"Ting, J. P. & Trowsdale, J. Genetic control of MHC class II expression. Cell 109, S21\u2013S33 (2002).","journal-title":"Cell"},{"key":"31356_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/jbmr.2090","volume":"29","author":"E Benasciutti","year":"2014","unstructured":"Benasciutti, E. et al. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity. J. Bone Min. Res. 29, 290\u2013303 (2014).","journal-title":"J. Bone Min. Res."},{"key":"31356_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","volume":"8","author":"J Delgado-Calle","year":"2014","unstructured":"Delgado-Calle, J., Bellido, T. & Roodman, G. D. Role of osteocytes in multiple myeloma bone disease. Curr. Opin. Support Palliat. Care 8, 407\u2013413 (2014).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"31356_CR14","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31356_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"31356_CR16","doi-asserted-by":"publisher","first-page":"21012","DOI":"10.1073\/pnas.1321210110","volume":"110","author":"MM Thi","year":"2013","unstructured":"Thi, M. M., Suadicani, S. O., Schaffler, M. B., Weinbaum, S. & Spray, D. C. Mechanosensory responses of osteocytes to physiological forces occur along processes and not cell body and require alphaVbeta3 integrin. Proc. Natl Acad. Sci. USA 110, 21012\u201321017 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31356_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrn3427","volume":"14","author":"J Graff","year":"2013","unstructured":"Graff, J. & Tsai, L. H. Histone acetylation: molecular mnemonics on the chromatin. Nat. Rev. Neurosci. 14, 97\u2013111 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"31356_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/bonekey.2013.95","volume":"2","author":"BL Clarke","year":"2013","unstructured":"Clarke, B. L. & Drake, M. T. Clinical utility of serum sclerostin measurements. Bonekey Rep. 2, 361 (2013).","journal-title":"Bonekey Rep."},{"key":"31356_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","volume":"25","author":"NS Raje","year":"2019","unstructured":"Raje, N. S., Bhatta, S. & Terpos, E. Role of the RANK\/RANKL pathway in multiple myeloma. Clin. Cancer Res. 25, 12\u201320 (2019).","journal-title":"Clin. Cancer Res."},{"key":"31356_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje, N. et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 19, 370\u2013381 (2018).","journal-title":"Lancet Oncol."},{"key":"31356_CR21","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.3389\/fimmu.2018.02467","volume":"9","author":"D Toscani","year":"2018","unstructured":"Toscani, D., Bolzoni, M., Ferretti, M., Palumbo, C. & Giuliani, N. Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy. Front Immunol. 9, 2467 (2018).","journal-title":"Front Immunol."},{"key":"31356_CR22","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","volume":"129","author":"MM McDonald","year":"2017","unstructured":"McDonald, M. M. et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 129, 3452\u20133464 (2017).","journal-title":"Blood"},{"key":"31356_CR23","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani, N. et al. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 26, 1391\u20131401 (2012).","journal-title":"Leukemia"},{"key":"31356_CR24","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1101\/gad.14.9.1156","volume":"14","author":"K Masternak","year":"2000","unstructured":"Masternak, K. et al. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14, 1156\u20131166 (2000).","journal-title":"Genes Dev."},{"key":"31356_CR25","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1128\/MCB.20.16.6051-6061.2000","volume":"20","author":"XS Zhu","year":"2000","unstructured":"Zhu, X. S. et al. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol. Cell Biol. 20, 6051\u20136061 (2000).","journal-title":"Mol. Cell Biol."},{"key":"31356_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/ni0903-819","volume":"4","author":"W Reith","year":"2003","unstructured":"Reith, W. ComPLEXIN new targets for CIITA. Nat. Immunol. 4, 819\u2013820 (2003).","journal-title":"Nat. Immunol."},{"key":"31356_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1101\/gad.5.4.670","volume":"5","author":"T Williams","year":"1991","unstructured":"Williams, T. & Tjian, R. Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev. 5, 670\u2013682 (1991).","journal-title":"Genes Dev."},{"key":"31356_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2005-6-13-246","volume":"6","author":"D Eckert","year":"2005","unstructured":"Eckert, D., Buhl, S., Weber, S., Jager, R. & Schorle, H. The AP-2 family of transcription factors. Genome Biol. 6, 246 (2005).","journal-title":"Genome Biol."},{"key":"31356_CR29","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673\u20132682 (2006).","journal-title":"J. Exp. Med."},{"key":"31356_CR30","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00198-009-1018-7","volume":"21","author":"V Breuil","year":"2010","unstructured":"Breuil, V. et al. Immune changes in post-menopausal osteoporosis: the Immunos study. Osteoporos. Int. 21, 805\u2013814 (2010).","journal-title":"Osteoporos. Int."},{"key":"31356_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bone.2008.02.017","volume":"43","author":"P D\u2019Amelio","year":"2008","unstructured":"D\u2019Amelio, P. et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 43, 92\u2013100 (2008).","journal-title":"Bone"},{"key":"31356_CR32","doi-asserted-by":"publisher","first-page":"10405","DOI":"10.1073\/pnas.1533207100","volume":"100","author":"S Cenci","year":"2003","unstructured":"Cenci, S. et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc. Natl Acad. Sci. USA 100, 10405\u201310410 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31356_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-1-4939-8997-3_3","volume":"1914","author":"JH Gooi","year":"2019","unstructured":"Gooi, J. H., Chia, L. Y., Vrahnas, C. & Sims, N. A. Isolation, purification, generation, and culture of osteocytes. Methods Mol. Biol. 1914, 39\u201351 (2019).","journal-title":"Methods Mol. Biol."},{"key":"31356_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2144\/0000113876","volume":"52","author":"AR Stern","year":"2012","unstructured":"Stern, A. R. et al. Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice. Biotechniques 52, 361\u2013373 (2012).","journal-title":"Biotechniques"},{"key":"31356_CR35","doi-asserted-by":"crossref","unstructured":"D. E. Maridas, E. Rendina-Ruedy, P. T. Le, C. J. Rosen, isolation, culture, and differentiation of bone marrow stromal cells and osteoclast progenitors from mice. J. Vis. Exp., (2018).","DOI":"10.3791\/56750"},{"key":"31356_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/cdd.2017.144","volume":"25","author":"J Gao","year":"2018","unstructured":"Gao, J. et al. SIRT3\/SOD2 maintains osteoblast differentiation and bone formation by regulating mitochondrial stress. Cell Death Differ. 25, 229\u2013240 (2018).","journal-title":"Cell Death Differ."},{"key":"31356_CR37","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cmet.2015.09.010","volume":"22","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. Endocrine relay by IGFBP1 promotes osteoclastogenesis and mediates FGF21-induced bone resorption. Cell Metab. 22, 811\u2013824 (2015).","journal-title":"Cell Metab."},{"key":"31356_CR38","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC Ozdemir","year":"2014","unstructured":"Ozdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719\u2013734 (2014).","journal-title":"Cancer Cell"},{"key":"31356_CR39","first-page":"5419","volume":"46","author":"DA Budwit-Novotny","year":"1986","unstructured":"Budwit-Novotny, D. A. et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 46, 5419\u20135425 (1986).","journal-title":"Cancer Res."},{"key":"31356_CR40","doi-asserted-by":"crossref","unstructured":"L. Zhang et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci. Transl. Med. 11, (2019).","DOI":"10.1126\/scitranslmed.aau1167"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31356-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31356-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:59:48Z","timestamp":1669294788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31356-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31356"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31356-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"3 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3684"}}